Compare TUYA & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | ALVO |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | China | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | TUYA | ALVO |
|---|---|---|
| Price | $2.01 | $4.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.49 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.0M | 721.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.76 | $13.28 |
| Revenue Next Year | $11.90 | $18.63 |
| P/E Ratio | $27.45 | ★ $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.87 | $2.94 |
| 52 Week High | $2.88 | $9.94 |
| Indicator | TUYA | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 64.02 |
| Support Level | N/A | $3.09 |
| Resistance Level | $2.48 | $5.46 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 40.85 | 76.06 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness. All the Group's revenue are derived from within the PRC.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.